Development and validation of an in vitro–in vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations

Center for Drug Evaluation and Research (CDER), USFDA, 1997 Center for Drug Evaluation and Research (CDER), USFDA, 1997 Eddington, 1998, Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets, Pharm Dev Technol, 3, 535, 10.3109/10837459809028636 Lu, 2011, In vitro-in vivo correlation: perspectives on model development, Int J Pharm, 418, 142, 10.1016/j.ijpharm.2011.01.010 Hayes, 2004, Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC), J Pharm Sci, 93, 571, 10.1002/jps.10552 Emami, 2006, In vitro-in vivo correlation: from theory to applications, J Pharm Pharm Sci, 9, 169 Mahayni, 2000, Evaluation of “external” predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate, J Pharm Sci, 89, 1354, 10.1002/1520-6017(200010)89:10<1354::AID-JPS13>3.0.CO;2-P Mandal, 2007, In-vitro and in-vivo correlation for two gliclazide extended-release tablets, J Pharm Pharmacol, 59, 971, 10.1211/jpp.59.7.0009 Mendyk, 2013, Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks, Drug Des Devel Ther, 7, 223, 10.2147/DDDT.S41401 Sirisuth, 2002, The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets, Eur J Pharm Biopharm, 53, 301, 10.1016/S0939-6411(01)00248-X Huang, 2004, Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation, Eur J Pharm Biopharm, 58, 607, 10.1016/j.ejpb.2004.03.037 Semple, 1994, Simplified high-performance liquid chromatographic method for propranolol and five metabolites in liver perfusate, rat serum and dog plasma, J Chromatogr B Biomed Appl, 655, 293, 10.1016/0378-4347(94)00064-6 Center for Drug Evaluation and Research (CDER), USFDA, 1997 Dutta, 2005, Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC), J Pharm Sci, 94, 1949, 10.1002/jps.20387 Chen, 1991, The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect, Pharm Res, 8, 25, 10.1023/A:1015865920043 Chen, 1995, The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect, Pharm Res, 12, 700, 10.1023/A:1016259509257 Jackson, 2000, The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect, Pharm Res, 17, 1432, 10.1023/A:1007581016352 Keller, 1989, Saturable first-pass kinetics of propranolol, J Clin Pharmacol, 29, 240, 10.1002/j.1552-4604.1989.tb03320.x